Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Recombination Signal Sequence (RSS) is a conserved DNA motif located adjacent to the Variable (V), Diversity (D), and Joining (J) gene segments within the immunoglobulin and T-cell receptor loci (Schatz & Swanson, 2011). Each RSS consists of a conserved heptamer and nonamer separated by a non-conserved spacer of either 12 or 23 base pairs, which dictates the 12/23 rule of recombination (Gellert, 2002). This sequence is specifically recognized and bound by the RAG1/RAG2 endonuclease complex, which initiates the DNA double-strand breaks necessary for V(D)J recombination (Teng & Papavasiliou, 2007). This process is essential for generating the vast diversity of the adaptive immune system's antigen receptors. While the RSS is not a traditional target for pharmacological agents, its proper function is critical for immune health; mutations in these sequences can lead to Severe Combined Immunodeficiency (SCID) (Notarangelo, 2010). Conversely, mistargeted RAG activity at RSS-like sequences (cryptic RSS) can lead to chromosomal translocations, a hallmark of many lymphoid leukemias and lymphomas (Helmink & Sleckman, 2012). Understanding the RSS-RAG interaction is vital for developing strategies to mitigate genomic instability and for advancing gene therapy approaches in primary immunodeficiencies.
The RSS serves as the specific recognition and binding site for the RAG1/RAG2 endonuclease complex; RAG1 binds the nonamer, and the complex introduces double-strand breaks at the heptamer-coding segment junction to initiate V(D)J recombination (Schatz & Swanson, 2011).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Recombination signal sequence (RSS).